Legend Biotech Q1 Adj. EPS $(0.07) Beats $(0.23) Estimate, Sales $195.05M Beat $193.62M Estimate
Earnings Scheduled For May 13, 2025
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
Biomarin Pharma Announces New VOXZOGO Data Showing Tibial Bowing Improvement In Achondroplasia
Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress
Joint Statement on U.S.-China Economic and Trade Meeting in Geneva
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
8 Analysts Have This To Say About Natera
Natera Analyst Ratings
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Natera Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance Above Estimates.
Natera GAAP EPS of -$0.50 Beats by $0.12, Revenue of $501.8M Beats by $55.13M
RBC Capital Maintains Sector Perform on Bio-Techne, Lowers Price Target to $63
FDA Advisory Panel to Discuss Makeup of Updated COVID Shots
Natera To Present Multiple Datasets In Breast Cancer Together With Collaborators At 2025 ESMO Breast Cancer Annual Congress In Munich
Here Are the Major Earnings After the Close Today
Bio-Techne Analyst Ratings
Kytopen And Bio-Techne Partner To Streamline Gene Delivery Solutions For Development And Manufacture Of Advanced Cell Therapies
Breaking Down Veracyte: 7 Analysts Share Their Views
Needham Maintains Buy on Veracyte, Lowers Price Target to $41